Relax, J&J--Eliquis may be surging, but Xarelto's safe for now

Pfizer ($PFE) and Bristol-Myers Squibb's ($BMY) new-age anticoagulant, Eliquis, has been ramping up after a slow start, growing 2014 sales to $774 million from $146 million the year prior. But Johnson & Johnson ($JNJ), maker of market leader Xarelto, need not worry, Bernstein analyst Ronny Gal says, thanks to that med's wide base of indications and hefty clinical trials program. More from FiercePharmaMarketing